An Open-Label Trial of Riluzole in Patients
With Treatment-Resistant Major Depression

Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK,
Luckenbaugh D, Charney DS, Manji HK.
Am J Psychiatry. 2004 Jan 1;161(1):171-174


OBJECTIVE: This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression. METHOD: After a 1-week drug-free period, subjects 18 years or older with a diagnosis of recurrent major depression and a Montgomery-Asberg Depression Rating Scale score >/==" BORDER="0">20 received riluzole monotherapy (100-200 mg/day) openly for 6 weeks. RESULTS: Nineteen treatment-resistant depressed patients, 53% of whom were classified as having stage 2 treatment resistance or greater, received riluzole at a mean dose of 169 mg/day. Significant improvement occurred during weeks 3 through 6 for all patients and weeks 2 through 6 for completers. CONCLUSIONS: Although preliminary, these results indicate that riluzole may have antidepressant properties in some patients.
NMDA antagonists
Glutamate and GABA
Schizoaffective disorder
Schizophrenia: new drugs
Glutamate and depression
Glutamate-modulating drugs for mood disorders

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family